// App-Quantinova.ai

P-15 : Histology classification highlights the difference in the effectiveness of S-1 over capecitabine when combined with cisplatin in patients with HER2-negative unresectable advanced or recurrent gastric cancer with measurable disease

Researchers

Presenter

  • H. Kawakami

Principal Investigators

  • K. Nishikawa

  • T. Shimokawa

  • K. Fujitani

  • S. Tamura

  • S. Endo

  • M. Kobayashi

  • J. Kawada

  • Y. Kurokawa

  • A. Tsuburaya

  • T. Yoshikawa

  • J. Sakamoto

  • T. Satoh

Medical Centers

  • Yao Municipal Hospital,Osaka, Japan

  • Osaka University Graduate School of Medicine, Osaka, JAPAN

  • Wakayama Medical University, Wakayama, Japan

  • KAWASAKI MEDICAL SCHOOL, Kurashiki, Japan

  • Department of Frontier Science for Cancer and Chemotherapy, Osaka University, Suita, Japan

  • Department of Surgery, Kochi Medical School, Nankoku, Japan

  • Kindai University Faculty of Medicine, Osakasayama, Japan

  • Osaka General Medical Center, Osaka, Japan

  • Sakai City Medical Center, Sakai, Japan

  • National Cancer Center Hospital, Tokyo, Japan

  • Ozawa hospital, Odawara, Japan

  • Tokai Central Hospital, Kakamigahara, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Capecitabine

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved